Annovis Bio, Inc.
ANVSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Annovis Bio, Inc. focuses on Biotechnology services and products. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The $42.6M market capitalization puts ANVS squarely in micro-cap range for its industry. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Market Cap
$42.6M
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
-1.16
EPS (TTM)
$-1.75
EPS (Fwd)
$-0.86
ROE
-703.7%
ROA
-142.4%
Cash
$18.7M
Total Debt
$0
Free CF
-$23.8M
52W Change
-53.5%
Annual Financials
Cash vs Debt
Where ANVS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANVS finished 45.76% below its 150-day moving average ($1.77) and 52.71% below its 200-day moving average ($2.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANVS overbought or oversold?
At the October 20, 2026 close, ANVS's RSI(14) was 21.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Annovis Bio, Inc. reports $18.7M in cash and $0 in total debt. Free cash flow is running at -$23.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -703.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Annovis Bio, Inc.'s trajectory.